Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 123,978 |
|
|||||
| News | - | ||||||
| Day High | 15.79 | Low High |
|||||
| Day Low | 15.13 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| LENZ Therapeutics Inc | LENZ | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.22 | -1.42% | 15.29 | 17:55:49 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 15.49 | 15.13 | 15.79 | 15.29 | 15.51 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 2,426 | 123,978 | $ 15.43 | $ 1,913,291 | - | 15.00 - 24.59 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:08:45 | average | 210 | $ 15.29 | USD |
LENZ Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 892.56M | 58.00M | - | 0 | -124.65M | -2.15 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
LENZ Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical LENZ Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 15.09 | 16.26 | 15.09 | 15.53 | 192,395 | 0.20 | 1.33% |
| 1 Month | 16.74 | 19.915 | 15.00 | 16.26 | 193,673 | -1.45 | -8.66% |
| 3 Months | 15.98 | 24.59 | 15.00 | 17.30 | 159,329 | -0.69 | -4.32% |
| 6 Months | 15.98 | 24.59 | 15.00 | 17.30 | 159,329 | -0.69 | -4.32% |
| 1 Year | 15.98 | 24.59 | 15.00 | 17.30 | 159,329 | -0.69 | -4.32% |
| 3 Years | 15.98 | 24.59 | 15.00 | 17.30 | 159,329 | -0.69 | -4.32% |
| 5 Years | 15.98 | 24.59 | 15.00 | 17.30 | 159,329 | -0.69 | -4.32% |
LENZ Therapeutics Description
| Graphite Bio Inc is a clinical-stage gene-editing company harnessing gene integration to develop a new class of therapies to cure serious and life-threatening diseases. Its gene-editing platform allows to precisely correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. Its lead product candidate GPH101 is a differentiated approach with the potential to directly correct the mutation that causes sickle cell disease (SCD) and restore normal adult hemoglobin (HgbA) expression. All of the company's long-lived assets are based in the United States. |
